Sourcebio Share Discussion Threads

[brummy_git] 08/3/2022 12:44

Highly synergistic acquisition by SourceBio today.

All the news & commentary here.

www.linkedin.com/posts/paul-hill-a5994116_sbi-nhs-nhs-activity-6906941945223213056-zuy0

[arthur_lame_stocks] 08/3/2022 10:52

Anyone got an opinion on today's acquisition? Apparantly it's going to be earnings enhancing but we'll see.

I'm not so fond of the share buyback, it may just give Chris Mills a chance to dump more of his shares without budging the price.

Still at least it's not all COVID here.

[km18] 07/3/2022 12:30

...from last month...

Company overview:

Sourcebio International is a laboratory services provider for clients in the clinical, life science research and biopharma industries.  As a result, human tissue testing services, genomics services and histopathology reporting services are intuitively covered and offered to biotechnological companies and pharmaceuticals. These enriching initiatives and highly stimulating laboratory services were efficiently reflected on the firm’s financial performance, as full year results will be substantially ahead of market expectations. Consequently, it implies that revenue is expected to reach £92.4m, resulting in an 82% hike with respect to the previous revenue of £50.7m in 2020. This plausible corporate news suggested that EBITDA leapt to £24.1m and thereby soared 70%, in relation to the EBITDA of £14.2m derived in 2020. Furthermore, the firm’s net cash position was simultaneously ahead of market expectations and stood at £33.3m, higher than the £8.4m net cash generated in 2020. From a valuation perspective, Sourcebio International derived an attractive P/E ratio of 22.9x, which is lower than the healthcare sector P/E ratio of 26.3x, signifying that the Sourcebio International is undervalued with respect to the healthcare sector, hence it is cheaply available for investors to purchase the stock, since it is expected to surge in value.

Brief Analysis:

EBITDA of £24.1m.
P/E ratio of 22.9x, lower than the healthcare sector benchmark
Revenue of £92.4m, higher than last year.
Net cash of £33.3m, substantially above previous year...

...from WealthOracleAM

[smithless] 10/2/2022 16:09

Most probably Mills moving stock between funds to make them look better

[9degrees] 04/2/2022 11:10

do all these share transfers have any significance?

[brummy_git] 22/1/2022 03:59

SBI (starts 13:15) discussed by Paul Hill & Justin Waite of Vox markets here

www.youtube.com/watch?v=gA_6tDwJA5k

[brummy_git] 22/1/2022 03:53

SBI discussed by Jamie Constable of Singer Capital markets & Paul Hill here (starts 14:50)

www.linkedin.com/posts/paul-hill-a5994116_singer-capital-markets-macro-update-january-activity-6890241940429123584-VgtD

[brummy_git] 18/1/2022 15:21

SBI update here from earlier

www.linkedin.com/posts/paul-hill-a5994116_sbi-covid-activity-6889142251608428544-RFf_

[redwing1] 18/1/2022 10:38

9degrees - market makers simply respond to supply and demand. They don't have a crystal ball. The share price is unmoved across two days simply because bulls of the good figures today are being offset by concerns regarding the outlook for covid testing in 2022.

Over to you. 'Buy' if you think the core prospects and cash to invest justify the current mkt cap and 'sell' if you think the drop off in 'exceptional' pcr test sales will be the key driver of the shares. Tricky one.

[9degrees] 18/1/2022 09:34

typical MM's reduce the share price the day before good results so they can then put it up to what it was once the results are out!
agree base7

[base7] 18/1/2022 08:20

I would have thought that C-19 was always viewed as a division which arose to exploit the opportunities ,which has enabled us to thrive during this period, build a substantial cash balance, provide developmental capital for our core businesses & allow us to make strategic acquisitions with the benefit of a large bank balance .
Lets hope any acquisitions made excite The Market & allow a decent re rate

[scepticalinvestor] 18/1/2022 07:22

Not bad at all! Only bought in last week too

[jaf111] 18/1/2022 07:14

Good update......make that a very very good update!

[boonboon] 18/1/2022 07:08

Good update. Only downer is rumours that travel testing is to be abolished soon.

[9degrees] 16/1/2022 23:14

tomorrow update ? could be a real cracker !!

[ptolemy] 11/1/2022 15:06

Last year we had a Trading Update on 18 January and an Investor presentation on
13 January. Hopefully, an update is due....

[base7] 23/12/2021 09:15

Lombard Odier & Griffithincreasing their holdings would help take out any weak holders .
Our cash balance will be increasing further apart from growth in our other 3 divisions which should result in a re rating .Mail recommended SBI as a tip for 21-which turned out to be a poor call but they may reiterate for 22 ,as may other analysts as other stocks benefitting from increased testing have done very well recently while we have stagnated.Doubled my modest(for me )holding yesterday

[rivaldo] 23/12/2021 08:29

Good to see Christopher Mills talking up SBI.

Further coverage here not posted before:



"SourceBio will get boost from PCR testing upsurge as Omicron spreads, predicts broker

The rolling average weekly PCR tests conducted is the 2nd highest since the pandemic began

Mon 13 Dec 2021

SourceBio International is well placed to benefit from the latest surge in PCR tests for Covid sparked by the Omicron variant, according to analysts at Liberum.

PCR testing volume in the UK has steadily grown in recent months with the rolling average weekly PCR tests conducted of 454,000 now the second-highest since the pandemic began, said the broker.

UK travel requirements mean that all arrivals must complete a Day 2 PCR test through an approved provider, a list that includes SourceBio.

In October, SourceBio’s PCR test was endorsed by Which? as the best provider of affordable Day 2 testing and ‘the most reliable choice for consumers.

The reintroduction of a mandatory Day 8 PCR test for UK arrival is also said to be under consideration by the government.

With the base business also now trading at pre-pandemic levels, Lberum believes SourceBio should meet forecasts for revenues this year of £86.5mln and underlying profits [EBITDA] of £21mln with potential to do even better in 2022 if more testing becomes the norm.

An update on trading is expected in early 2022 and Liberum sees potential for forecasts to be raised and has a buy rating and target price of 190p."

[donmac101] 22/12/2021 18:20

Middle of january results.

[mungorock] 22/12/2021 11:24

When will the next update come out?

[brummy_git] 22/12/2021 11:08

Christopher Mills talks positively about Sourcebio (03:00) here.

www.linkedin.com/feed/update/urn:li:activity:6879354290515841026/

www.youtube.com/watch?v=cG7_82WZdmc&t=2135s

[base7] 21/12/2021 16:06

Dont they manufacture their own PCR & LF tests at their Nottingham facility - which is why they can sell for less than many of the competition & remain top of the Which best buy list ?The pressure on them therefore is to keep their internal supply up with demand so should be busier than ever resulting in an unexpectedly strong end of the year from testing.

[boonboon] 16/12/2021 20:52

No tests available. Hopefully they can sort out capacity/supply issues. https://coviduk.sourcebioscience.com/Thanks

[rivaldo] 16/12/2021 14:02

Cheers donmac101 - here's a link:



"We are experiencing extremely high levels of inquiries and demand for our COVID-19 Testing Services"